Physicians' Academy for Cardiovascular Education


Slides (presentation) - Apr. 28, 2011


is a first-in-class apo-B synthesis inhibitor currently in late-stage development. It is intended to reduce LDL-C by preventing the formation of atherogenic lipids. It acts by decreasing the production of apo-B, which provides the structural core for all atherogenic lipids, including LDL-C, which carry cholesterol through the bloodstream

New Approaches to Lipid management
Phase I (first in man) Design: Normal Volunteers with Mild Hypercholesterolemia
Dose Dependent Reduction in ApoB vs. Time
Dose Dependent Reduction in Small Dense LDL-C vs. Time

Share this page with your colleagues and friends: